6.7
Adrenerge Agonisten: Wirkstoffe mit gemischter Wirkung
Gemischt wirkende adrenerge Agonisten wie Ephedrin und Pseudoephedrin beeinflussen direkt und indirekt adrenerge Rezeptoren. Diese Mittel stimulieren…
Misch wirkende adrenerge Agonisten wirken direkt, indem sie Adrenozeptoren stimulieren, und indirekt, indem sie gespeicherte Katecholamine aus den Nervenendigungen freisetzen.
Im Gegensatz zu endogenen Katecholaminen fehlt gemischt wirkenden Agonisten eine Catechol-Einheit, was sie zu schlechten Substraten für die Verstoffwechselung von Enzymen macht, wodurch ihre Wirkungsdauer verlängert wird.
Sowohl Ephedrin als auch Pseudoephedrin weisen eine ausgezeichnete orale Bioverfügbarkeit und ZNS-Penetration auf, sind aber weniger wirksam als Katecholamine.
Ephedrin – isoliert aus der Ephedra-Pflanze – wurde als oral wirksames Sympathomimetikum zur Behandlung von Asthma eingesetzt.
Da Ephedrin eine Herzstimulation und Vasokonstriktion verursacht, wird es zur Behandlung von anästhesieinduzierter Hypotonie eingesetzt. Es ist jedoch ein weniger wirksamer Bronchodilatator als Isoprenalin oder Adrenalin.
Darüber hinaus sind seine zentralen stimulierenden Wirkungen für seinen Missbrauch als Leistungsverstärker verantwortlich.
Pseudoephedrin – ein Ephedrin-Isomer mit indirekter Wirkung – ist oral wirksam und hat weniger ZNS-Wirkungen. Es wird hauptsächlich als abschwellendes Mittel verwendet.
Da es häufig als Ausgangsstoff für die illegale Produktion von Methamphetamin verwendet wird, ist sein Verkauf streng reguliert.
View the full transcript and gain access to JoVE Core videos
Q1: How do mixed-acting adrenergic agonists differ from direct-acting agents?
Mixed-acting adrenergic agonists both stimulate adrenoceptors directly and indirectly release stored catecholamines from nerve terminals, amplifying the adrenergic response. Direct-acting agents only bind to receptors. Mixed-acting agents like ephedrine and pseudoephedrine lack a catechol moiety, making them resistant to metabolic degradation and extending their duration of action compared to endogenous catecholamines.
Q2: Why do ephedrine and pseudoephedrine have better oral bioavailability than catecholamines?
Ephedrine and pseudoephedrine lack a catechol moiety, which makes them poor substrates for metabolizing enzymes. This structural difference prevents rapid degradation, increasing their oral bioavailability and allowing them to reach systemic circulation effectively. Their lipophilicity also enhances absorption and CNS penetration, though they remain less potent than endogenous catecholamines.
Q3: What are the main clinical uses of ephedrine?
Ephedrine is used orally as a sympathomimetic agent for treating asthma and managing anesthesia-induced hypotension due to its cardiac stimulation and vasoconstriction effects. However, it is a less potent bronchodilator than isoprenaline or adrenaline. Its central stimulatory effects have led to abuse as a performance enhancer, limiting its therapeutic application.
Q4: Why is pseudoephedrine primarily used as a decongestant rather than for asthma?
Pseudoephedrine, an ephedrine isomer with predominantly indirect action, is orally effective with fewer central nervous system effects than ephedrine. These reduced CNS effects make it suitable for nasal decongestant use without significant stimulatory side effects. Its indirect mechanism of action and safety profile favor its use for congestion relief over asthma treatment.
Q5: How does prior catecholamine depletion affect mixed-acting agonist response?
Mixed-acting adrenergic agonists depend on releasing stored neurotransmitters for their indirect effects. Prior treatment with catecholamine-depleting agents like guanethidine or reserpine significantly reduces the agonist response by eliminating available stored catecholamines. This demonstrates the importance of the indirect mechanism in mixed-acting agent efficacy.
Q6: Why is pseudoephedrine's sale strictly regulated?
Pseudoephedrine is commonly used as a precursor in illegal methamphetamine production. Due to this abuse potential, its sale is strictly regulated to prevent diversion for illicit drug synthesis. Despite its legitimate therapeutic use as a decongestant, regulatory restrictions limit its availability and distribution.
Q7: What structural feature allows mixed-acting agonists to resist enzymatic degradation?
Mixed-acting adrenergic agonists like ephedrine and pseudoephedrine lack a catechol moiety present in endogenous catecholamines. This absence makes them poor substrates for metabolizing enzymes, preventing rapid degradation and increasing their duration of action. This structural modification is key to their extended therapeutic effect compared to natural catecholamines.